Medical oncology · Ireland
A 52-year-old woman with a pT1c pN0 M0, oestrogen-receptor-positive, HER2-negative invasive ductal carcinoma asked whether adjuvant chemotherapy was necessary in addition to endocrine therapy.
Following breast-conserving surgery and sentinel lymph node biopsy, the histology reported a 1.6 cm grade 2 invasive ductal carcinoma, ER 8/8, PR 6/8, HER2 immunohistochemistry 1+, Ki-67 18%, margins clear, 0/3 sentinel nodes involved. The patient had been offered adjuvant chemotherapy followed by five years of an aromatase inhibitor and wanted to understand the reasoning before deciding.
“Does the pathology in this case indicate a genomic recurrence-risk assay, and how is the absolute benefit of adjuvant chemotherapy usually estimated alongside endocrine therapy?”
Dates are expressed as intervals rather than calendar dates, and identifying details have been altered, so that the sequence of care can be followed without identifying the patient.
Month 0
Routine screening mammogram recalled for a 14 mm spiculated mass in the upper outer quadrant of the left breast; ultrasound and core biopsy performed the same day (one-stop clinic).
Month 0 + 6 days
Grade 2 invasive ductal carcinoma of no special type, ER 8/8, PR 6/8, HER2 immunohistochemistry 1+ (negative), Ki-67 18%.
Month 1
Breast MRI showed unifocal disease; no distant staging indicated for clinical stage I. Multidisciplinary team recommended breast-conserving surgery with sentinel lymph node biopsy.
Month 2
Wide local excision and sentinel node biopsy. Final histology pT1c (16 mm), pN0 (0/3 nodes), margins clear at 4 mm, no lymphovascular invasion.
Month 3
Patient offered adjuvant chemotherapy followed by adjuvant radiotherapy and five years of an aromatase inhibitor. She asked for time to consider.
Month 3 + 4 days
Records uploaded through the encrypted portal; AI-assisted summary generated and routed to a consultant medical oncologist in active breast practice.
Month 3 + 8 days
Signed written report returned with a plain-language summary, a reasoning section and a prepared question list for the treating oncologist.
Month 4
Patient attended her own oncology clinic with the report; a genomic recurrence-risk assay was arranged locally and the adjuvant plan was agreed with her treating oncologist.
Every item supplied by the patient was indexed before review. Nothing was assessed in isolation from the rest of the record.
Lesion size and BI-RADS category cross-checked against the surgical specimen size.
Receptor status, grade and Ki-67 confirmed against the definitive resection report.
Reviewed for multifocality and contralateral disease.
pT and pN category, margin width and lymphovascular invasion status verified.
Compared with the histology to confirm the stated stage matched the recorded pathology.
Reviewed for the stated rationale and for what had been discussed about absolute benefit.
Baseline fitness parameters relevant to any chemotherapy discussion.
Every report ends with a prepared question list. The questions are written to be asked of the patient's own clinician — they are prompts for discussion, not recommendations.
Extracts from the signed specialist report, reproduced in the same section order used in every MedReview 365 report.
The patient returned to her treating oncologist with a written summary and a prepared question list. Her own team confirmed a genomic assay was available locally and the decision was made within that consultation. The treatment decision remained entirely with her treating clinicians.
This case study is anonymised, published with patient consent and altered where necessary to prevent identification. It describes how one written second opinion was prepared and discussed. It is not a treatment recommendation, not a diagnosis, and not an indication of any expected result in another patient. Always discuss your care with your own treating clinician, and seek emergency care for urgent or deteriorating symptoms.